Last reviewed · How we verify
NCT04119973
A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China
trial testing standard treatment in Thrombelastography in 486 participants. Completed in 4 November 2019.
4 August 2019
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 486 |
| Start date | 16 August 2018 |
| Primary completion | 4 August 2019 |
| Estimated completion | 4 November 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- standard treatment
Conditions studied
- Thrombelastography — all drugs for Thrombelastography →
- Acute on Chronic Liver Failure — all drugs for Acute on Chronic Liver Failure →
- Platelet — all drugs for Platelet →
- Multicenter Prospective Study — all drugs for Multicenter Prospective Study →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 18 to 80, any sex, with Thrombelastography or Acute on Chronic Liver Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. And through the platelet mapping, it can help provide a picture of patients' function of platelet. Based on the primary result of our derivation cohort(NCT03281278), ACLF patients with high ADP inhibition rate had high 28-day mortality.This multicenter validation cohort aims to validate the predictive role of platelet mapping in ACLF prognosis, organ failure developments and short term mortality.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Design for a Multicentre Prospective Cohort for the Assessment of Platelet Function in Patients with Hepatitis-B-Virus-Related Acute-on-Chronic Liver Failure.
Jiang X, Chai S, Huang Y, Huang Z, et al · · 2022 · cited 1× · PMID 36042872 · DOI 10.2147/clep.s376068
Verify or expand the search:
- PubMed search for NCT04119973
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of standard treatment
Trials testing the same drug.
- NCT07236645 — Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy · Phase 2 · not yet recruiting
- NCT07172100 — To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-a · Phase 2 · enrolling by invitation
- NCT07045883 — Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss · NA · active not recruiting
- NCT06961201 — Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-s · Phase 3 · not yet recruiting
- NCT06872034 — The Efficacy and Safety of Venostan in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures · NA · recruiting
Other recruiting trials for Thrombelastography
Currently open trials in the same condition.
- NCT06635564 — Personalized ViscoElastic Testing-guided Bleeding Management In Liver Surgery, Neurosurgery and Obstetrics · recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04119973 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 9 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04119973.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing